Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxter/Cerus Pathogen Inactivation PMA Set Back Two Years For More Data

This article was originally published in The Gray Sheet

Executive Summary

Baxter/Cerus expects the supplemental pivotal trial of its Intercept blood platelet pathogen inactivation system to take 15-18 months to complete

You may also be interested in...



Navigant Pathogen Inactivation System Catching Up With Cerus, Vitex

Navigant Biotechnologies is dedicating $10 mil. in 2004 to the development of its Mirasol riboflavin-based pathogen reduction technology (PRT) for platelets and red blood cells

Navigant Pathogen Inactivation System Catching Up With Cerus, Vitex

Navigant Biotechnologies is dedicating $10 mil. in 2004 to the development of its Mirasol riboflavin-based pathogen reduction technology (PRT) for platelets and red blood cells

Cerus Pathogen Inactivation Trial Delay Alters Landscape For Vitex, Navigant

Uncertainty over Baxter/Cerus' Intercept red blood cell pathogen reduction program may benefit competitor Vitex, which is pursuing the same indication for its Inactine device

Related Content

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel